Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved IMDELLTRA™ (tarlatamab-dlle) for the treatment of adult patients with... THOUSAND OAKS ...

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE) drugs for solid tumours.

FDA approval of tarlatamab (Imdelltra) for small-cell lung cancer offers ... Another BiTE in development by Amgen binds CD3 ...

Also Read: Amgen/AstraZeneca’s Asthma Drug Tezspire Vs. Sanofi/Regeneron’s Blockbuster Dupixent – Analyst Gives His Pick WAYPOINT is a randomized, double-blind trial that evaluated the ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Dr. Goss has received research funding from AstraZeneca and Roche Pharmaceuticals and has served as a paid consultant or been on an Advisory Board for Amgen, AstraZeneca, Pfizer Inc., and Roche ...